Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer

1. Phase III ALASCCA trial: Demonstrates 51% reduced risk of colorectal cancer recurrence with adjuvant daily aspirin. 2. First study to show somatic alterations in the PI3K pathway predict aspirin response, expanding the targetable patient population. 3. ALASCCA trial: 3,508 patients with early-stage colorectal cancer screened for PI3K pathway alterations. 4. Adverse effects: Aspirin deemed safe, with expected well-known side effects. 5. Dr. Ciombor's insight: Understanding the importance of patient selection regarding the findings of the ALASCCA study may take time for implementation. 6. National Comprehensive Cancer Network updated its guidelines to recommend aspirin for patients with PIK3CA mutations.